– Company is Profitable and Cash flow Positive from Operations for Second Quarter –  – UDENYCA ® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share – REDWOOD CITY, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.

REDWOOD CITY, Calif. , July 29, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the District of Delaware

REDWOOD CITY, Calif. , July 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective July 18, 2019 , the compensation committee of the company’s board of directors granted five new employees options to purchase an aggregate of 125,000 shares of the

REDWOOD CITY, Calif. , July 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that UDENYCA® preliminary unaudited net sales for the quarter that ended June 30, 2019 are expected to be in the range of $79.0 million to $84.0 million .

REDWOOD CITY, Calif. , July 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will be released after market close on Thursday, August 1, 2019 . Starting at 4:30 p.m.

REDWOOD CITY, Calif. , July 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The cumulative production of 400,000 UDENYCA ® pre-filled syringes is a

REDWOOD CITY, Calif. , June 21, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective June 20, 2019 , the compensation committee of the company’s board of directors granted eight new employees and two Vice Presidents options to purchase an aggregate of

REDWOOD CITY, Calif. , May 23, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective May 22, 2019 , the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 40,000 shares of the company’s

REDWOOD CITY, Calif. , May 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 5, 2019 at 10:00 a.m. ET .

REDWOOD CITY, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31 , 2019.  First Quarter 2019 Company Highlights •   UDENYCA®

Coherus Continues to Commercialize UDENYCA® Across All Segments REDWOOD CITY, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Amgen and Coherus have settled the trade secret action brought by Amgen against Coherus that was pending

REDWOOD CITY, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Bank of America Merrill Lynch Global

REDWOOD CITY, Calif. , April 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective April 18, 2019 , the compensation committee of the company’s board of directors granted six new employees, a Senior Vice President, and another Senior Vice President,

REDWOOD CITY, Calif. , April 05, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that UDENYCA™ preliminary unaudited net sales for the quarter that ended March 31, 2019 are expected to be in the range of $36.0 million to $38.0 million .

REDWOOD CITY, Calif. , April 05, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2019 financial results will be released after market close on Thursday, May 9, 2019 . Starting at 4:30 p.m.

REDWOOD CITY, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 12:10 p.m. GMT .

REDWOOD CITY, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 21, 2019, the compensation committee of the company’s board of directors granted two new employees options to purchase an aggregate of 10,000 shares of the

REDWOOD CITY, Calif. , March 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 13, 2019 , the compensation committee of the company’s board of directors granted the newly hired Chief Legal Officer an option to buy 225,000 shares of the

REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus’ legal

REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA™ (pegfilgrastim-cbqv) biosimilar for transitional pass-through payment status in the hospital outpatient

REDWOOD CITY, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31 , 2018.  Fourth Quarter 2018 and Recent Corporate Highlights Include: On November 2, 2018

REDWOOD CITY, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the 38 th Cowen & Company Healthcare Conference

REDWOOD CITY, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 21, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 47,000 shares of the

REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released after market close on Thursday, February 28, 2019 . Starting at 4:30 p.m.

REDWOOD CITY, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 6, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 40,000 shares of the

Complaint alleges Amgen infringes three U.S. patents recently awarded to Coherus REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (

- The settlement affords U.S. market entry of December 15, 2023 - REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has executed settlement agreements with AbbVie Inc.

REDWOOD CITY, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 10, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 68,000 shares of the

REDWOOD CITY, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners .

REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37 th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco .

REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton , M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019 . “We are very pleased that Dr.